Literature DB >> 32150687

How Closely Do Clinical Trial Participants Resemble "Real-World" Patients with Groups 2 and 3 Pulmonary Hypertension? A Structured Review.

Kari R Gillmeyer1,2, Seppo T Rinne1,2, Allan J Walkey2, Shirley X Qian1, Renda Soylemez Wiener1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32150687      PMCID： PMC7258417          DOI： 10.1513/AnnalsATS.202001-003RL

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  16 in total

1.  Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.

Authors:  Ganesh Raghu; Steven D Nathan; Juergen Behr; Kevin K Brown; James J Egan; Steven M Kawut; Kevin R Flaherty; Fernando J Martinez; Athol U Wells; Lixin Shao; Huafeng Zhou; Noreen Henig; Javier Szwarcberg; Hunter Gillies; Alan B Montgomery; Thomas G O'Riordan
Journal:  Eur Respir J       Date:  2015-08-06       Impact factor: 16.671

2.  Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada.

Authors:  D Thiwanka Wijeratne; Katherine Lajkosz; Susan B Brogly; M Diane Lougheed; Li Jiang; Ahmad Housin; David Barber; Ana Johnson; Katharine M Doliszny; Stephen L Archer
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-02

3.  Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

Authors:  Steven D Nathan; Jürgen Behr; Harold R Collard; Vincent Cottin; Marius M Hoeper; Fernando J Martinez; Tamera J Corte; Anne M Keogh; Hanno Leuchte; Nesrin Mogulkoc; Silvia Ulrich; Wim A Wuyts; Zhen Yao; Francis Boateng; Athol U Wells
Journal:  Lancet Respir Med       Date:  2019-08-12       Impact factor: 30.700

4.  Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.

Authors:  Elke S Hoendermis; Licette C Y Liu; Yoran M Hummel; Peter van der Meer; Rudolf A de Boer; Rolf M F Berger; Dirk J van Veldhuisen; Adriaan A Voors
Journal:  Eur Heart J       Date:  2015-07-17       Impact factor: 29.983

5.  Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors.

Authors:  Athanasios Charalampopoulos; Luke S Howard; Ioanna Tzoulaki; Wendy Gin-Sing; Julia Grapsa; Martin R Wilkins; Rachel J Davies; Petros Nihoyannopoulos; Susan B Connolly; J Simon R Gibbs
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

6.  Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

Authors:  Diana Bonderman; Stefano Ghio; Stephan B Felix; Hossein-Ardeschir Ghofrani; Evangelos Michelakis; Veselin Mitrovic; Ronald J Oudiz; Francis Boateng; Andrea-Viviana Scalise; Lothar Roessig; Marc J Semigran
Journal:  Circulation       Date:  2013-06-17       Impact factor: 29.690

7.  Phosphodiesterase-5 Inhibitor Therapy for Pulmonary Hypertension in the United States. Actual versus Recommended Use.

Authors:  Deborah Kim; Kyung Min Lee; Marc R Freiman; W Ryan Powell; Elizabeth S Klings; Seppo T Rinne; Donald R Miller; Adam J Rose; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2018-06

8.  Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.

Authors:  Javier Bermejo; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subías; José Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Eduardo de Teresa; José R González-Juanatey; Arturo Evangelista; Teresa Mombiela; Ana González-Mansilla; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés
Journal:  Eur Heart J       Date:  2018-04-14       Impact factor: 29.983

9.  Pulmonary hypertension due to left heart disease.

Authors:  Jean-Luc Vachiéry; Ryan J Tedford; Stephan Rosenkranz; Massimiliano Palazzini; Irene Lang; Marco Guazzi; Gerry Coghlan; Irina Chazova; Teresa De Marco
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

10.  Pulmonary hypertension in chronic lung disease and hypoxia.

Authors:  Steven D Nathan; Joan A Barbera; Sean P Gaine; Sergio Harari; Fernando J Martinez; Horst Olschewski; Karen M Olsson; Andrew J Peacock; Joanna Pepke-Zaba; Steeve Provencher; Norbert Weissmann; Werner Seeger
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671
View more
  4 in total

1.  Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy.

Authors:  Shelsey W Johnson; Kari R Gillmeyer; Rendelle E Bolton; Megan B McCullough; Shirley X Qian; Bradley A Maron; Elizabeth S Klings; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2022-07

2.  Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease.

Authors:  Kari R Gillmeyer; Donald R Miller; Mark E Glickman; Shirley X Qian; Elizabeth S Klings; Bradley A Maron; Joseph T Hanlon; Seppo T Rinne; Renda S Wiener
Journal:  Pulm Circ       Date:  2021-04-01       Impact factor: 3.017

3.  Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing.

Authors:  Shelsey W Johnson; Lauren Finlay; Stephen C Mathai; Ronald H Goldstein; Bradley A Maron
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

4.  Demographic and Health Behavior Factors Associated With Clinical Trial Invitation and Participation in the United States.

Authors:  Courtney P Williams; Nicole Senft Everson; Nonniekaye Shelburne; Wynne E Norton
Journal:  JAMA Netw Open       Date:  2021-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.